Novel Flt-3/KDR inhibitor is effective against activated Flt-3 and is cytotoxic against Flt-3-driven leukemias in vitro and in vivo
Stephen C. Beck(United States Military Academy), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Toby Johnson(North Devon District Hospital), Marian Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), Małgorzata Wójtowicz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth A. Thomas(United States Military Academy), Jennifer M. Shipman(Johns Hopkins University), Nancy E. Kohl(United States Military Academy), Sarah Y. Liou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aimée Dallob(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Deutsch, Bo‐Sheng Pan(United States Military Academy), Keith Rickert(United States Military Academy), Kathryn Mazina(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathleen Coll(United States Military Academy), W. Wayt Gibbs(United States Military Academy), Qinwen Zeng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dale Schaar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bin Shi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Maricel Torrent(United States Military Academy), Lenora J. Davis(Institute of Cancer Research), Mary Flynn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Schina(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wesley Tanaka(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yih Lee(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cancer Research
April 1, 2004
Cited by 0
Related Papers
(untitled)
|Edinburgh Research Explorer (University of Edinburgh)|0|2.3k
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
|Nature|2011|2.1k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k